Brief: Hungary's Richter and Hikma receive FDA approval for denosumab biosimilars
29/09/2025 07:05
BUDAPEST, Sept 29 (Reuters) - Richter Gedeon Vegyeszeti Gyar Nyrt GDRB.BU says in a statement: RICHTER AND HIKMA RECEIVE FDA APPROVAL FOR DENOSUMAB BIOSIMILARS ENOBYTM AND XTRENBO, REFERENCING PROLIA AND XGEVA, RESPECTIVELY UNDER THE TERMS OF THE AGREEMENT RICHTER IS RESPONSIBLE FOR THE DEVELOPMENT AND MANUFACTURE OF THE PRODUCTS HIKMA IS RESPONSIBLE FOR THE FDA REGISTRATION AND EXCLUSIVE COMMERCIALIZATION IN THE U.S. DENOSUMAB IS INDICATED FOR TREATING OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN Source text: [https://www.bse.hu/newkibdata/129324268/Denosumab_FDA_Approval_Sep2025_EN.pdf] Further company coverage: GDRB.BU (Reporting by Anita Komuves) ((KOMUVES.Anita@thomsonreuters.com;))
Recent news on Richter Gedeon Vegyeszeti Gyar Nyrt
See all newsAI in Hungary could unlock productivity gains of €15 billion, McKinsey says
Brief: Hungary's Richter and Hetero announce cooperation for development of semaglutide injection
Brief: Hungary's Richter and Acrux agree to license transdermal Estradiol spray for Australia
Brief: Hungary's Richter Says 2026 Guidance Fully Reiterated High-Single-Digit Growth In Revenues And Clean EBIT (At Constant Exchange Rates)
Brief: Hungary's Richter says European Commission granted approval for Tuyory, its biosimilar to Tocilizumab